Valuation: Mesoblast Limited

Market Cap 2.65B 1.83B 1.63B 1.5B 1.36B 2.58B 172B 17.98B 7.17B 91.82B 6.87B 6.72B 289B P/E 2027 *
-56.1x
P/E 2028 * 98.6x
Enterprise Value 2.75B 1.9B 1.7B 1.56B 1.42B 2.69B 178B 18.68B 7.45B 95.42B 7.14B 6.98B 301B EV / Sales 2027 *
11.2x
EV / Sales 2028 * 7.63x
Free-Float
63.36%
Yield 2027 *
-
Yield 2028 * -
1 day+1.96%
1 week-3.70%
Current month-7.96%
1 month+0.97%
3 months-11.86%
6 months+4.00%
Current year-23.53%
1 week 2.02
Extreme 2.02
2.2
1 month 1.74
Extreme 1.735
2.38
Current year 1.74
Extreme 1.735
3.31
1 year 1.74
Extreme 1.735
3.31
3 years 0.26
Extreme 0.255
3.37
5 years 0.26
Extreme 0.255
3.37
10 years 0.26
Extreme 0.255
5.7
Manager TitleAgeSince
Chief Executive Officer 69 23/03/2011
Director of Finance/CFO 59 17/11/2025
Chief Tech/Sci/R&D Officer - 11/03/2026
Director TitleAgeSince
Director/Board Member 69 01/01/2007
Director/Board Member 75 15/04/2013
Director/Board Member 79 06/03/2014
Date Insider Type Main position Quantity % Market Cap. Importance
19/08/26 Free

Director

875,000 0.0674%
17/07/26 Exercice

Founder

1,885,334 0.1456%
17/07/26 Exercice

Founder

-1,885,334 0.1456%
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%-3.70%-9.17%+462.16% 1.83B
+2.24%+8.40%+58.47%+69.00% 68.22B
+0.40%+8.62%+14.98%+88.60% 59.82B
+0.76%+1.84%+24.38%+98.51% 56.07B
+2.55%+15.52%+30.43%+120.17% 47.67B
+2.58%+7.89%+32.49%+45.30% 45.95B
+4.09%+6.37%+228.06%+899.75% 43.29B
-0.47%+9.38%+27.53%+52.40% 35.66B
+0.38%-1.56%+95.20%+70.04% 34.73B
+1.48%+6.21%-38.80%+395.73% 25.47B
Average +1.58%+6.17%+46.36%+230.16% 42B
Weighted average by Cap. +1.59%+7.77%+53.38%+185.13%

Financials

2027 *2028 *
Net sales 245M 169M 151M 139M 126M 239M 15.88B 1.66B 663M 8.5B 636M 622M 26.77B 366M 253M 226M 208M 189M 357M 23.7B 2.48B 990M 12.69B 949M 929M 39.97B
Net income -34.35M -23.73M -21.18M -19.49M -17.69M -33.52M -2.22B -233M -92.92M -1.19B -89.06M -87.15M -3.75B 56.89M 39.3M 35.08M 32.28M 29.29M 55.52M 3.68B 386M 154M 1.97B 147M 144M 6.21B
Net Debt 104M 71.88M 64.16M 59.04M 53.58M 102M 6.74B 706M 281M 3.61B 270M 264M 11.36B 143M 98.83M 88.21M 81.17M 73.67M 140M 9.26B 971M 387M 4.96B 371M 363M 15.62B
Projected Income Statement - Annual - Mesoblast Limited
Logo Mesoblast Limited
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Employees
108
Date Price Change Volume
10/11/26 A$2.080 +1.96% 2,658,570
09/11/26 A$2.040 +0.49% 2,310,883
06/11/26 A$2.030 -6.45% 2,548,051
05/11/26 A$2.170 +3.33% 3,273,099
04/11/26 A$2.100 -2.78% 2,612,414
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Mesoblast Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.040AUD
Average target price
3.507AUD
Spread / Average Target
+71.90%